{"nctId":"NCT03651765","briefTitle":"Long Term Extension Trial of Setmelanotide","startDateStruct":{"date":"2018-07-15","type":"ACTUAL"},"conditions":["Obesity Associated With Defects in Leptin-melanocortin Pathway"],"count":205,"armGroups":[{"label":"Setmelanotide","type":"EXPERIMENTAL","interventionNames":["Drug: Setmelanotide"]}],"interventions":[{"name":"Setmelanotide","otherNames":["RM-493"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Participants aged 2 or older (or aged \\>2 years as per local regulations) who had completed participation in a previous setmelanotide trial and demonstrated adequate safety and meaningful clinical benefit (efficacy)\n2. Participant and/or parent or guardian was able to communicate with the investigator, understand and sign the written informed consent/assent, and comply with the trial requirements\n3. Agree to use a highly effective form of contraception throughout the trial\n\nKey Exclusion Criteria:\n\n1. Pregnant and/or breastfeeding women\n2. Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)\n3. Current, clinically significant disease\n4. Documented diagnosis of schizophrenia, bipolar disorder, personality disorder, major depressive disorder, or other psychiatric disorder(s)\n5. Suicidal ideation, attempt or behavior\n6. History of significant liver disease\n7. Moderate to severe renal dysfunction as defined by a glomerular filtration rate (GFR)\\<30 milliliters per minute (mL/min).\n8. History or close family history of melanoma or participant history of oculocutaneous albinism\n\nOther protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A TEAE was defined as any AE that began or worsened in intensity on or after the date of the first administration of study drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":205},"commonTop":["Skin Hyperpigmentation","Covid-19","Headache","Injection Site Erythema","Melanocytic Naevus"]}}}